To include your compound in the COVID-19 Resource Center, submit it here.

Sanofi makes case for why its first cancer drug in a decade can take on Darzalex

The French pharma lays out its strategy for re-entering oncology, bolstered by new Sarclisa data

Carving a space in the crowded multiple myeloma market for recently approved Sarclisa is one of the four pillars of Sanofi’s strategy for re-entering oncology, and the company believes new data strengthen the case for the CD38 inhibitor.

On Tuesday, Sanofi (Euronext:SAN; NASDAQ:SNY) shared data from the Phase III IKEMA study in advance of the European Hematology Association Virtual Congress showing efficacy rates for Sarclisa isatuximab in a new combination with carfilzomib and dexamethasone that point to a potential advantage over other CD38 inhibitors.

In the second-line or greater setting in

Read the full 905 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers